Tags

Type your tag names separated by a space and hit enter

Long-acting and selective suppression of growth hormone secretion by somatostatin analogue SMS 201-995 in acromegaly.
Lancet. 1984 Oct 06; 2(8406):782-4.Lct

Abstract

In 6 of 7 acromegalic patients a single subcutaneous injection of 50 micrograms of a new octapeptide somatostatin analogue (SMS 201-995) reduced serum growth hormone (GH) from 30 +/- 12 ng/ml to 1.4 +/- 0.4 (mean +/- SEM). Serum GH remained below basal concentration for 9 h. In the remaining patient who had very high basal preprandial serum GH, SMS 201-995 produced a reduction in serum GH of only 20%. Plasma glucose concentrations were increased to the upper limits of the normal range when a high-carbohydrate meal was consumed 2 h after injection. In non-diabetic patients plasma glucose did not exceed 129 mg/dl. The 40% decrease in plasma glucagon, which lasted for 7 h after SMS 201-995 injection, was not statistically significant. No side-effects and no rebound phenomenon were observed. These results suggest that SMS 201-995 may be the first somatostatin analogue suitable for the clinical management of acromegaly.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

6148524

Citation

Plewe, G, et al. "Long-acting and Selective Suppression of Growth Hormone Secretion By Somatostatin Analogue SMS 201-995 in Acromegaly." Lancet (London, England), vol. 2, no. 8406, 1984, pp. 782-4.
Plewe G, Beyer J, Krause U, et al. Long-acting and selective suppression of growth hormone secretion by somatostatin analogue SMS 201-995 in acromegaly. Lancet. 1984;2(8406):782-4.
Plewe, G., Beyer, J., Krause, U., Neufeld, M., & del Pozo, E. (1984). Long-acting and selective suppression of growth hormone secretion by somatostatin analogue SMS 201-995 in acromegaly. Lancet (London, England), 2(8406), 782-4.
Plewe G, et al. Long-acting and Selective Suppression of Growth Hormone Secretion By Somatostatin Analogue SMS 201-995 in Acromegaly. Lancet. 1984 Oct 6;2(8406):782-4. PubMed PMID: 6148524.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Long-acting and selective suppression of growth hormone secretion by somatostatin analogue SMS 201-995 in acromegaly. AU - Plewe,G, AU - Beyer,J, AU - Krause,U, AU - Neufeld,M, AU - del Pozo,E, PY - 1984/10/6/pubmed PY - 1984/10/6/medline PY - 1984/10/6/entrez SP - 782 EP - 4 JF - Lancet (London, England) JO - Lancet VL - 2 IS - 8406 N2 - In 6 of 7 acromegalic patients a single subcutaneous injection of 50 micrograms of a new octapeptide somatostatin analogue (SMS 201-995) reduced serum growth hormone (GH) from 30 +/- 12 ng/ml to 1.4 +/- 0.4 (mean +/- SEM). Serum GH remained below basal concentration for 9 h. In the remaining patient who had very high basal preprandial serum GH, SMS 201-995 produced a reduction in serum GH of only 20%. Plasma glucose concentrations were increased to the upper limits of the normal range when a high-carbohydrate meal was consumed 2 h after injection. In non-diabetic patients plasma glucose did not exceed 129 mg/dl. The 40% decrease in plasma glucagon, which lasted for 7 h after SMS 201-995 injection, was not statistically significant. No side-effects and no rebound phenomenon were observed. These results suggest that SMS 201-995 may be the first somatostatin analogue suitable for the clinical management of acromegaly. SN - 0140-6736 UR - https://www.unboundmedicine.com/medline/citation/6148524/Long_acting_and_selective_suppression_of_growth_hormone_secretion_by_somatostatin_analogue_SMS_201_995_in_acromegaly_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0140-6736(84)90706-2 DB - PRIME DP - Unbound Medicine ER -